Accurus Biosciences
Accurus Biosciences is a privately held Bay Area contract research organization offering therapeutic antibody discovery, mammalian recombinant protein production, stable cell line generation, and antibody engineering services and catalog products to pharmaceutical and biotechnology clients.
- Company typePrivate
- Founded-
- HeadquartersRichmond, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Accurus Biosciences does
Accurus Biosciences, Inc. is a privately held contract research organization headquartered at 2600 Hilltop Drive in Richmond, California (San Francisco Bay Area), focused on therapeutic antibody discovery and mammalian protein expression services for pharmaceutical and biotechnology companies. The company was founded by Dr. Richard Zhang (Chief Executive Officer) and Dr. Haishan Lin (Co-founder), both industry veterans with over 20 years of experience developing proteins and antibodies for therapeutic applications. The workforce is small (1-10 employees) and the company is not publicly listed; no parent organization, institutional funding rounds, or ownership changes are disclosed in the available data.
The company's core technology is built around mammalian protein expression platforms using CHO and HEK293 cells, supported by proprietary expression vector systems, a highly efficient electrofusion-based hybridoma generation process, and single-cell cloning by FACS. Services span the full therapeutic antibody workflow — therapeutic antibody discovery (hybridoma, screening by ELISA/FACS/functional assays, hybridoma sequencing), recombinant protein and antibody production (transient HEK293 and stable CHO), stable cell line generation (CHO, HEK293, MDCK, NS0), antibody humanization, antibody and protein engineering (hot spot removal, effector function optimization, bispecifics, half-life extension), cell-based assays, and molecular biology — with documented turnarounds of 3-6 weeks for recombinant proteins and 8-10 weeks for stable cell lines. Accurus also sells a catalog of recombinant proteins, research-grade monoclonal antibodies (including clones against CLDN18.2, CD47, DDR1, EGFR, HER2, FOLR1, TIGIT, RNF43, B7-H3, B7-H4, CCR8), and pre-generated stable cell lines.
Accurus operates a hybrid go-to-market model: catalog products are sold online via a direct e-commerce storefront with global cold-chain shipment, while custom services (antibody discovery, humanization, engineering, stable cell line generation) are quote-based and handled through direct inquiry. Pricing for products ranges from roughly $175 to $875 per antibody aliquot and $4,000 to $7,500 per recombinant protein or stable cell pool, with engineering and large-scale services priced on inquiry. Revenue derives from three streams — contract research services, catalog research product sales, and antibody technology licensing — the last demonstrated by a January 2024 exclusive worldwide licensing agreement with ImmPACT Bio covering a designated CLDN18.2 antibody for CAR T-cell therapy development. No financial terms, revenue figures, or backlog disclosures are available in the source material.
Accurus Biosciences firmographics
Firmographics- Name
- Accurus Biosciences
- Legal name
- Accurus Biosciences, Inc.
- Website
- https://accurusbio.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Accurus Biosciences is a privately held Bay Area contract research organization offering therapeutic antibody discovery, mammalian recombinant protein production, stable cell line generation, and antibody engineering services and catalog products to pharmaceutical and biotechnology clients.
- Ownership category
- akta.pro rank
Accurus Biosciences industry classification
Industry- Product category
- Biologics Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Accurus Biosciences is headquartered
LocationHeadquarters
- HQ city
- Richmond
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Accurus Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Contract Research Services: Fee-for-service therapeutic antibody discovery, recombinant protein production, stable cell line generation, antibody engineering, and cell-based assay services sold to pharma and biotech companies.
- Research Products: Sale of catalog products including recombinant proteins, antibodies, and stable cell lines for research use.
- Technology Licensing: Licensing of antibody intellectual property (e.g., CLDN18.2 antibody) to partners for therapeutic development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Recombinant Protein Transient Production (HEK293) |
| Unit Pricing | Pay-as-you-go | Recombinant Protein Stable Production (CHO) |
| Unit Pricing | Pay-as-you-go | Recombinant Antibody Transient Production (HEK293) |
| Unit Pricing | Pay-as-you-go | Recombinant Antibody Stable Production (CHO) |
| Unit Pricing | Pay-as-you-go | Membrane Protein Transient Expression (HEK293) |
| Other | Pay-as-you-go | Antibody Engineering Services |
| Other | Pay-as-you-go | Protein Engineering Services |
| Unit Pricing | Pay-as-you-go | Stable Cell Line Generation Services |
| Unit Pricing | Pay-as-you-go | Antibody Products (Research Use) |
| Unit Pricing | Pay-as-you-go | Stable Cell Line Products |
| Unit Pricing | Pay-as-you-go | Isotype Control (Human IgG4) |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Accurus Biosciences product offering
Product offeringCore offering
Accurus Biosciences is a contract research organization (CRO) that provides therapeutic antibody discovery, recombinant protein and antibody production in mammalian systems (CHO and HEK293), stable cell line generation, antibody humanization, antibody and protein engineering, cell-based assays, and molecular biology services to pharmaceutical and biotechnology companies. The company also manufactures and sells catalog research products including recombinant proteins, monoclonal antibodies (anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT and others), pre-made stable cell lines, and mammalian cell transfection reagents. Services are delivered from its Richmond, California facility with catalog pricing for standard offerings and quote-based pricing for custom engagements.
Product overview
Accurus Biosciences is a protein therapeutics discovery service company offering a comprehensive suite of services encompassing therapeutic antibody discovery, recombinant protein and antibody production (both transient and stable expression in CHO and HEK293 cells), stable cell line generation (using CHO-S, HEK293, MDCK, NS0, and EL4 host cells), antibody and protein engineering (including bispecific antibodies, hot spot removal, and half-life extension), antibody humanization, cell-based assays, and molecular biology services. The company also manufactures and sells physical products including recombinant proteins, antibodies (such as anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT antibodies), and pre-generated stable cell lines. Services are offered as standalone offerings or integrated packages, with catalog-based pricing and custom service options.
Differentiator
Problem solved
Functional benefit
Products and services
- Therapeutic Antibody Discovery Full-service therapeutic antibody lead discovery using proprietary hybridoma electrofusion, antigen design and immunization, screening by ELISA/FACS/functional assays, hybridoma sequencing, and chimeric antibody production. Sold to pharma and biotech clients seeking antibody leads for therapeutic development.
- Recombinant Protein and Antibody Production High-quality mammalian protein expression and purification services using proprietary production cell lines and expression vectors, supporting both transient (HEK293) and stable (CHO) expression at scales from 0.1L to >1L. Delivered to pharma, biotech, and academic customers with 3–6 week turnarounds and >95% purity.
- Stable Cell Line Generation
- Antibody and Protein Engineering Engineering services covering antibody expression optimization, CDR/framework hot spot removal, Fc effector function optimization (CDC, ADCC, phagocytosis), bispecific antibody design (scFv-scFv, antibody-scFv, heterodimeric IgGs), protein half-life extension (Fc/HSA/PEG fusions), mutagenesis, and epitope tagging. Sold to therapeutic antibody and protein developers.
- Antibody Humanization Humanization of monoclonal antibody leads and molecular engineering for optimal therapeutic properties and function. Sold to antibody developers preparing candidates for clinical development.
- Cell-Based Assays
- Molecular Biology Services
- Recombinant Proteins (catalog)
- Research Antibodies (catalog)
- Pre-made Stable Cell Lines (catalog)
- Mammalian Cell Transfection and Expression Reagents
- CLDN18.2 Antibody Out-licensing Program Out-licensing of Accurus' proprietary CLDN18.2 monoclonal antibody portfolio (clones D10C, E9, T158S2 and others) to partners for therapeutic development, including the January 2024 exclusive worldwide license to ImmPACT Bio for CAR T-cell therapy applications targeting solid tumors.
Quantifiable outcome
- Purity >95% for recombinant proteins and antibodies as determined by SDS-PAGE or HPLC
- +3 more outcomes
Companies that use Accurus Biosciences
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Accurus Biosciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Accurus Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ImmPACT BiocoreAccurus Biosciences has granted exclusive worldwide rights to ImmPACT Bio to develop and commercialize next generation cell therapies using a designated antibody from Accurus' CLDN18.2 antibody portfolio. Accurus retains the rights to develop and commercialize its CLDN18.2 antibody portfolio for all non-cell based therapeutic applications. The partnership enables ImmPACT Bio to leverage Accurus' potentially best-in-class CLDN18.2 antibody for CAR T-cell therapy development targeting solid tumors.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Accurus Biosciences competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Vancouver-based antibody discovery CRO/platform combining proprietary screening with mammalian expression for therapeutic antibody programs. Directly comparable in service offering (antibody discovery → engineering) and target customer base (pharma/biotech).
- ImmunoPrecise Antibodies: Specialty CRO offering therapeutic antibody discovery, custom protein production, and cell line generation. Closely comparable in service mix (hybridoma, recombinant antibodies, stable cell lines) and in serving biotech/pharma customers.
Broad incumbents
- GenScript: Large life-science services provider offering gene synthesis, recombinant protein/antibody production, and cell line engineering. Overlaps Accurus' catalog products and custom services at much larger scale.
- WuXi Biologics: Global biologics CRO/CDMO with end-to-end discovery through manufacturing services including antibody discovery, protein production, and stable cell line generation. Comparable service stack and customer set.
- Lonza: Global CDMO offering mammalian protein production and cell line development services. Comparable in CHO-based expression, stable cell line generation, and antibody manufacturing capabilities.
- Catalent: Major biopharmaceutical CDMO with biologics capabilities including cell line development and biotherapeutic protein production. Competes in the same upstream mammalian expression and cell line services space.
- Eurofins Discovery: Discovery and bioanalytical services arm of Eurofins offering antibody and protein services. Comparable in CRO services for pharma/biotech but at significantly larger scale and broader scope.
Emerging players
- ProMab Biotechnologies: Mid-sized CRO focused on custom monoclonal antibody development, hybridoma generation, and protein production. Comparable niche CRO serving similar biotech customers with similar service mix.
- Creative Biolabs: Specialty CRO offering antibody discovery (hybridoma, phage display), protein engineering, and cell line services. Comparable scope and target customer profile, though with broader modality coverage.
- ProteoGenix: Specialty CRO offering recombinant protein and antibody production in mammalian systems plus antibody engineering services. Closely comparable in service offering, host systems (CHO/HEK293), and customer profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Accurus Biosciences social profiles
Digital presenceAccurus Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accurus Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
Accurus Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accurus Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accurus Biosciences
What does Accurus Biosciences do?
Accurus Biosciences is a contract research organization (CRO) that provides therapeutic antibody discovery, recombinant protein and antibody production in mammalian systems (CHO and HEK293), stable cell line generation, antibody humanization, antibody and protein engineering, cell-based assays, and molecular biology services to pharmaceutical and biotechnology companies. The company also manufactures and sells catalog research products including recombinant proteins, monoclonal antibodies (anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT and others), pre-made stable cell lines, and mammalian cell transfection reagents. Services are delivered from its Richmond, California facility with catalog pricing for standard offerings and quote-based pricing for custom engagements.
Is Accurus Biosciences a public or private company?
Accurus Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Accurus Biosciences founded?
Accurus Biosciences was founded in -1. It employs 1 to 10 people.
Where is Accurus Biosciences based?
Accurus Biosciences is headquartered in Richmond, United States, in the North America region.
How does Accurus Biosciences make money?
Three revenue lines are on record. Contract Research Services are the primary driver. The others are research Products and technology Licensing.
Who are Accurus Biosciences's main competitors?
Direct peers on record are AbCellera Biologics and ImmunoPrecise Antibodies. Broad incumbents are GenScript, WuXi Biologics, Lonza, Catalent and Eurofins Discovery. Emerging players are ProMab Biotechnologies, Creative Biolabs and ProteoGenix.
Does Accurus Biosciences have an API?
No public API is recorded for Accurus Biosciences.
What industry is Accurus Biosciences in?
Accurus Biosciences's product category is Biologics Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 2835.